Blab Business
XORTX Therapeutics Announces Chairman Anthony Giovinazzos Resignation from Board
On July 31, 2026, XORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX, Frankfurt: ANU) announced that Anthony Giovinazzo, who has chaired the board for several years, would step down for personal reasons and to pursue other interests. Giovinazzo’s resignation is effective immediately.
In a statement, co‑CEO Dr. Allen Davidoff expressed gratitude: “XORTX management and the board of directors extend our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman during the past several years. Anthony’s contribution to XORTX spans leadership and ethics of the highest standards as Board chairman, and on key committees. We personally thank him for his time with the Company.”
XORTX is a Calgary‑based, late‑stage clinical biopharmaceutical company that develops therapies for gout and progressive kidney disease. Its pipeline features three clinically advanced programs: XRx‑026 for gout, XRx‑008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx‑101 for acute kidney injury linked to respiratory viral infections. In addition, the company is advancing a pre‑clinical program, XRx‑225, for type 2 diabetic nephropathy, and has recently acquired the VB4‑P5 program—still in the pre‑IND stage—that targets both rare and common forms of kidney disease.
XORTX’s strategy centers on correcting aberrant purine metabolism and inhibiting xanthine oxidase to curb uric acid production. The company has positioned XRx‑026 as a proprietary oxypurinol formulation intended to be as safe and effective as allopurinol, and it plans to file a New Drug Application with the U.S. Food and Drug Administration in 2026.
The board resignation is a routine corporate‑governance event. XORTX has not named a successor for Giovinazzo, and the co‑CEO structure—led by Dr. Allen Davidoff and Mika Grasso—remains unchanged. The company will continue to pursue its clinical development milestones and regulatory submissions as outlined in recent filings.
Forward‑looking statements in the press release highlight expectations regarding capital needs, regulatory approvals, and the ability to attract qualified personnel. These statements are subject to risks and uncertainties, including the company’s ability to secure additional funding and to obtain regulatory approval for its product candidates.
Giovinazzo’s departure does not affect XORTX’s day‑to‑day operations or its publicly listed status. Shares of XRTX trade on the NASDAQ and TSXV, and the company is also listed in Frankfurt. Investors and stakeholders can review the company’s most recent annual report and ongoing filings for detailed risk disclosures.
As XORTX moves forward, the company remains focused on delivering innovative treatments for patients with gout and kidney disease. The board will continue to oversee strategy, and the leadership team will maintain its commitment to advancing the pipeline and engaging with regulators.
The resignation of Chairman Giovinazzo marks a governance transition but does not alter XORTX’s developmental trajectory or its commitment to improving patient outcomes in purine metabolism and renal disease.
In a statement, co‑CEO Dr. Allen Davidoff expressed gratitude: “XORTX management and the board of directors extend our heartfelt appreciation for Mr. Giovinazzo’s efforts as chairman during the past several years. Anthony’s contribution to XORTX spans leadership and ethics of the highest standards as Board chairman, and on key committees. We personally thank him for his time with the Company.”
XORTX is a Calgary‑based, late‑stage clinical biopharmaceutical company that develops therapies for gout and progressive kidney disease. Its pipeline features three clinically advanced programs: XRx‑026 for gout, XRx‑008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx‑101 for acute kidney injury linked to respiratory viral infections. In addition, the company is advancing a pre‑clinical program, XRx‑225, for type 2 diabetic nephropathy, and has recently acquired the VB4‑P5 program—still in the pre‑IND stage—that targets both rare and common forms of kidney disease.
XORTX’s strategy centers on correcting aberrant purine metabolism and inhibiting xanthine oxidase to curb uric acid production. The company has positioned XRx‑026 as a proprietary oxypurinol formulation intended to be as safe and effective as allopurinol, and it plans to file a New Drug Application with the U.S. Food and Drug Administration in 2026.
The board resignation is a routine corporate‑governance event. XORTX has not named a successor for Giovinazzo, and the co‑CEO structure—led by Dr. Allen Davidoff and Mika Grasso—remains unchanged. The company will continue to pursue its clinical development milestones and regulatory submissions as outlined in recent filings.
Forward‑looking statements in the press release highlight expectations regarding capital needs, regulatory approvals, and the ability to attract qualified personnel. These statements are subject to risks and uncertainties, including the company’s ability to secure additional funding and to obtain regulatory approval for its product candidates.
Giovinazzo’s departure does not affect XORTX’s day‑to‑day operations or its publicly listed status. Shares of XRTX trade on the NASDAQ and TSXV, and the company is also listed in Frankfurt. Investors and stakeholders can review the company’s most recent annual report and ongoing filings for detailed risk disclosures.
As XORTX moves forward, the company remains focused on delivering innovative treatments for patients with gout and kidney disease. The board will continue to oversee strategy, and the leadership team will maintain its commitment to advancing the pipeline and engaging with regulators.
The resignation of Chairman Giovinazzo marks a governance transition but does not alter XORTX’s developmental trajectory or its commitment to improving patient outcomes in purine metabolism and renal disease.
